Word

IMMORNA

Status

Pending

Status Code

688

Status Date

Tuesday, December 26, 2023

Serial Number

97424017

Mark Type

4000

Filing Date

Monday, May 23, 2022

Published for Opposition

Tuesday, October 31, 2023

Trademark Owner History

Immorna Biotherapeutics Inc. - Owner At Publication

Classifications

40 Manufacture of nanoparticles and capsids for use in connection with mRNA-based therapeutics for others

5 Messenger RNA (mRNA) pharmaceutical and biopharmaceutical preparations for use in the treatment of oncological diseases and disorders, infectious diseases, autoimmune and genetic diseases and disorders, and for use in medical cosmetology; messenger RNA (mRNA) pharmaceutical and biopharmaceutical preparations for vaccines; Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; Pharmaceutical preparations and substances for the treatment of infectious diseases; vaccines; pharmaceutical preparations and substances for the treatment of autoimmune diseases and disorders, autoimmune deficiency; pharmaceutical preparation and substances for the treatment of genetic disorders; pharmaceutical preparations and substances for use in medical cosmetology; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic preparations for medical purposes for detecting the presence of tumors, infectious diseases, genetic disorders and autoimmune disorders and conditions; drug delivery agents in the form of polymer and lipid nanoparticles for delivery of mRNA being a pharmaceutical preparation; drug delivery agents in the form of nanoparticles and capsids for delivery for a wide variety of therapeutic agents

1 Reagents for scientific, research, and medical research use; chemical reagents other than for medical purposes; diagnostic reagents for clinical or medical laboratory use; mRNA reagents for scientific, research, and medical research use; reagents comprised of nanoparticles for scientific, research, and medical research use; reagents, comprised of capsids for scientific, research, and medical research use

42 Research and development of messenger RNA (mRNA) biotechnologies; Research and development services in the field of biologics, including but not limited to mRNA, RNA, DNA, antibodies, vaccines, and peptides; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostic services for scientific research purposes, and pharmacogenetics; conducting research and clinical trials for others in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostic services for scientific research purposes, and pharmacogenetics; Scientific research, namely, mRNA synthesis, purification and testing

Trademark Events

Dec 26, 2023

Noa E-Mailed - Sou Required From Applicant

Oct 31, 2023

Official Gazette Publication Confirmation E-Mailed

Oct 31, 2023

Published For Opposition

Oct 11, 2023

Notification Of Notice Of Publication E-Mailed

Sep 21, 2023

Approved For Pub - Principal Register

Sep 21, 2023

Teas/Email Correspondence Entered

Sep 21, 2023

Correspondence Received In Law Office

Sep 20, 2023

Assigned To Lie

May 2, 2023

Teas Response To Office Action Received

Mar 21, 2023

Notification Of Examiner's Amendment/Priority Action E-Mailed

Mar 21, 2023

Examiner's Amendment/Priority Action E-Mailed

Mar 21, 2023

Combined Examiner's Amendment/Priority Action Automatic Entry

Mar 21, 2023

Examiners Amendment And/Or Priority Action - Completed

Mar 10, 2023

Assigned To Examiner

May 26, 2022

New Application Office Supplied Data Entered

May 26, 2022

New Application Entered